SALT LAKE CITY, May 14, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, president and CEO, is scheduled to present at the Bank Of America Merrill Lynch 2013 Health Care Conference, at 10:00 a.m. Pacific on May 16, 2013, at the Encore at the Wynn in Las Vegas, Nevada. The presentation will be available to interested parties through a live audio webcast accessible through a link on the investor relations section of Myriad's Web site at www.myriad.com . About Myriad Genetics Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's portfolio of molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com .
CONTACT: Media Contact: Ron Rogers (801) 584-3065 firstname.lastname@example.org Investor Contact: Scott Gleason (801) 584-1143 email@example.com